Breast changes tell whether treatment works: study
By Maggie Fox, Health and Science Editor
WASHINGTON (Reuters) - It may be possible to predict which breast cancer patients will be helped by tamoxifen based on changes in so-called breast density, researchers reported on Saturday.
Women with dense breasts — a term meaning they have more non-fatty tissue — are known to have a higher risk of breast cancer and the study suggests that lowering density using tamoxifen also lowers the chances tumors will come back.
Women whose breasts became noticeably less dense after a year or so of taking tamoxifen had a 63 percent reduced risk of breast cancer, the team of British researchers told a breast cancer meeting in San Antonio, Texas.
“It is important to find a way to predict who will respond to tamoxifen, and changes in breast density may constitute an early indicator of benefit,” said Jack Cuzick of the Wolfson Institute of Preventive Medicine in London.
He said about 10 percent of women have dense breasts. Such breasts are harder to read on mammograms but there is evidence the tissue in their breasts may be more cancer-prone.
“Women with dense breasts are typically at four to five times the risk of developing breast cancer than women without dense breasts,” Cuzick told reporters in a telephone briefing.
Cuzick’s team had conducted one of many studies that showed high-risk women who took tamoxifen were at least 40 percent less likely to either develop breast cancer, or to have it come back.
They went back and looked at all the mammograms of the more than 1,000 women who took part in the study.
If a woman’s breast density did not change during the treatment, she was much more likely to develop cancer despite taking tamoxifen, Cuzick told the meeting.
TWO-THIRDS REDUCTION
“Women who lost 10 percent or more in breast density — 40 percent of the women getting tamoxifen — had a 63 percent, almost a two-thirds, reduction in all breast cancer,” he told the briefing.
Cuzick stressed the study only looked at tamoxifen and not at other treatments, such as the newer drugs known as aromatase inhibitors. But he said it validated the idea of using breast density as a way of telling whether a treatment is working, whether tamoxifen or something else.
“If a woman doesn’t show breast density dropping within a year or so, you might want to consider other therapy,” Cuzick said.
In another report, a team at the Mayo Clinic in Rochester, Minnesota said they found some clues as to why dense breast tissue is more likely to develop tumors.
Dense breast tissue contains more cells believed to give rise to breast cancer, Dr. Karthik Ghosh told the meeting. Continued…
--------------------------------------------------------------------------------------------Related Posts:
By Michael Kahn LONDON (Reuters) - British scientists have figured out why some women develop resistance to the most commonly used breast cancer drug, something that raises the risk their tumors will return, according to a study published on Wednesday. The findings could lead to new tests to determine which women are not likely to benefit from
Full Post: Scientists unravel breast cancer drug resistance
--------------------------------------------------------------------------------------------
By Will Dunham WASHINGTON (Reuters) - Women with a family history of breast cancer but who test negative for two genetic mutations commonly linked to it still have a very high risk of developing the disease, Canadian researchers said on Monday. These women are four times more likely to develop breast cancer than the average woman, translating
Full Post: Family history key in figuring breast cancer risk
--------------------------------------------------------------------------------------------
LONDON (Reuters) - The most commonly used breast cancer drug may cause tumors to spread in a small number of women with low levels of a protein which makes cells stick together, British researchers said on Thursday. The findings could lead to new tests to determine which women are not likely to benefit from tamoxifen and
Full Post: Study sheds light on breast cancer drug failure
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - Little breast tumors that seemed cured after surgery are more likely to come back if they are the type known as HER2 positive, U.S. researchers reported on Friday. They said women who have these types of tumors may need extra treatment with drugs such as Genentech Inc.’s Herceptin — which is not standard
Full Post: Small breast tumors might need more treatment: study
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - Certain breast cancer survivors who load up on fruits and vegetables, eating far more than current U.S. guidelines, can slash their risk the tumors will come back by nearly a third, according to a U.S. study released on Monday. The finding only held for women who did not have hot flashes after their
Full Post: Fruits, veggies slash breast cancer risk: U.S. study